Novo Nordisk

Scott Galloway: Why I'm selling my American stocks

My First Million

Pharmaceutical company cited as a potential source of GLP-1 drugs; Scott mentions estimating a macro policy scenario involving a billion doses.

How Sugar & Processed Foods Impact Your Health | Dr. Robert Lustig

Andrew Huberman

Pharmaceutical company that manufactures semaglutide (Ozempic/Wegovy).

E159: The Bestie Awards! Recapping the best and worst of 2023

All-In Podcast

Awarded Best Turnaround for sustained focus and investment over a decade, leading to significant stock growth (4-5x in four years) driven by semaglutide drugs like Ozempic and Wegovy, which are considered transformational.

E150: Israel/Gaza escalating or not? EU censorship regime, Penn donors revolt, GLP-1 hype cycle

All-In Podcast

Danish multinational pharmaceutical company, a developer of key GLP-1 drugs, discussed for its stock performance and the drug's impact.

No. 1 Sugar Expert: You've Been Sold A Lie About "Healthy" Food!

The Diary Of A CEO

In conversation with Robert F. Kennedy Jr.

All-In Podcast

Pharmaceutical company that co-funded the Danish government study on the DTP vaccine in West Africa.

Dave Ricks, CEO of Eli Lilly | The All-In Interview

All-In Podcast

A competitor in the diabetes and obesity drug market, particularly mentioned in relation to GLP-1 development and insulin pricing.

In conversation with Reid Hoffman & Robert F. Kennedy Jr.

All-In Podcast

Danish pharmaceutical company that produces Ozempic, criticized for lobbying to make Medicare cover its drug and its influence on diabetes treatment recommendations.

⚡️ How to turn Documents into Knowledge: Graphs in Modern AI — Emil Eifrem, CEO Neo4J

Latent Space

A company in the life sciences sector that uses Neo4j and has a case study involving over 60 million documents.

The Peptide Expert: Big Pharma Are Hiding This Powerful Peptide From You! - Dr. Alex Tatem

The Diary Of A CEO

A pharmaceutical company that, along with Lily, produces GLP-1 medications and is reportedly pressuring the FDA to crack down on compounded versions.